Particle Replication in Nonwetting Templates Nanoparticles with Tumor Selective Alkyl Silyl Ether Docetaxel Prodrug Reduces Toxicity
Source abstract
Abstract
Delivery systems designed to have triggered release after passively targeting the tumor may improve small molecule chemotherapeutic delivery. Particle replication in nonwetting templates was used to prepare nanoparticles to passively target solid tumors in an A549 subcutaneous xenograft model. An acid labile prodrug was delivered to minimize systemic free docetaxel concentrations and improve tolerability without compromising efficacy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Cancer Treatment and Pharmacology · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina 27607, United States
Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, United States
References (22)
Show source-provided references
1. Myer-Losic F. · Clin. Cancer Res. · 2008 · 14 · 214510.1158/1078-0432.CCR-07-4580 ↗
2. Gupta D. · Mol. Pharm. · 2013 · 10 · 51210.1021/mp300564v ↗
3. Lee Y. · J. Drug Target · 2012 · 20 · 52410.3109/1061186X.2012.693498 ↗
4. Chu K. S. · Nanomedicine · 2013 · 9 · 68610.1016/j.nano.2012.11.008 ↗
5. Tang L. · ACS Nano · 2012 · 6 · 395410.1021/nn300149c ↗
6. Li C. · Cancer Chemother. Pharmacol. · 2000 · 46 · 41610.1007/s002800000168 ↗
7. Feng L. · Int. J. Nanomed. · 2011 · 6 · 2545
8. Etrych T. · Mol. Pharm. · 2010 · 7 · 101510.1021/mp100119f ↗
9. Ma P. · Cancer Lett. · 2013 · 334 · 25310.1016/j.canlet.2012.08.009 ↗
10. Zhao H. · Bioconjugate Chem. · 2008 · 19 · 84910.1021/bc700333s ↗
11. Schluep T. · Cancer Chemother. Pharmacol. · 2006 · 57 · 65410.1007/s00280-005-0091-7 ↗
12. Younes A. · J. Clin. Oncol. · 2012 · 30 · 218310.1200/JCO.2011.38.0410 ↗
13. Chipman S. D. · Int. J. Nanomed. · 2006 · 1 · 37510.2147/nano.2006.1.4.375 ↗
14. Parrott M. C. · J. Am. Chem. Soc. · 2012 · 134 · 797810.1021/ja301710z ↗
15. Ali S. · Anticancer Drugs · 2001 · 12 · 11710.1097/00001813-200102000-00004 ↗
16. Huynh L. · Org. Biomol. Chem. · 2009 · 7 · 343710.1039/b906862g ↗
17. Wuts P. G. M. · 2007
18. Chu K. S. · Biomaterials · 2013 · 34 · 842410.1016/j.biomaterials.2013.07.038 ↗
19. Kellokumpu-Lehtinen P. L. · Lancet Oncol. · 2013 · 14 · 11710.1016/S1470-2045(12)70537-5 ↗
20. Lee S. W. · J. Controlled Release · 2011 · 155 · 26210.1016/j.jconrel.2011.06.012 ↗
21. Hrkach J. · Sci. Transl. Med. · 2012 · 4 · 128ra3910.1126/scitranslmed.3003651 ↗
22. Gradishar W. J. · J. Clin. Oncol. · 2005 · 23 · 779410.1200/JCO.2005.04.937 ↗